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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.04.002BACKGROUND: 14q32 rearrangement has been identified as a recurrent hotspot of translocations in multiple
myeloma (MM). The Fluorescence Immunophenotyping and Interphase Cytogenetics as a tool for the
Investigation of Neoplasms (known as FICTION technique) for evaluation of chromosomal changes in MM.
The aim of this work is to detect 14q32 rearrangement, using FICTION technique, on archival bone marrow
(BM) slides of MM patients, and to study its prognostic value.
METHOD: This study was conducted at Ain Shams University Hospital. The FICTION technique, which uses
CD138 and dual color, and the break-apart 14q32 rearrangement probe, was performed on archived smears
of BM slides for 50 MM patients at the time of diagnosis.
RESULTS: A significantly higher percentage of cases were positive for 14q32 rearrangement by FICTION (32%)
compared to fluorescence in situ hybridization (FISH) (12%) (p = 0.04). Cases positive by FICTION for the rear-
rangement were designated as Group A, while negative cases were designated as Group B. Significantly lower
Hb and CRP levels were found among Group B when compared to Group A patients (p = 0.001 and 0.01,
respectively). Serum albumin level and Bence Jones protein (BJP) significantly affect overall survival (OS)
(p = 0.01, 0.007, respectively). However, a statistically non-significant shorter mean survival time was found
in positive cases through FICTION versus negative cases.
CONCLUSION: FICTION technique provides a sensitive tool for establishing clonal plasma cells (PC) infiltra-
tion of BM aspirates, and is amenable for use on archived as well as fresh smears.
KEYWORDS: Multiple myeloma; Plasma cells; 14q32 rearrangement; FICTION; Archived smearsMultiple myeloma (MM) is characterized bya clonal proliferation of malignant,immunoglobulin (Ig) producing plasma
cells (PCs) in the bone marrow (BM).1
It has been reported that all MM patients harbor
cytogenetic abnormalities, sometimes during the course
of the disease.1The chromosomal 14q32 region has been
identiﬁed as a recurrent hotspot of translocations in
myeloma.2 However, this is not speciﬁc to MM as the
chromosomal 14q32 region abnormalities are alsodetected in mantle cell lymphoma and chronic T-cell
leukemia.3 These abnormalities are involving the
immunoglobulin heavy chain (IgH) locus at chromo-
some 14q32, and one of several partner genes.4 14q32
rearrangements can be detected by conventional as well
as molecular cytogenetic methods, such as FISH.
Conventional cytogenetic analysis of the BM is an
important tool in evaluating karyotype abnormalities
in MM. However, due to the in vitro hypo-
proliferative nature of the myeloma, it is not alwaysarter 2015
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possible to obtain good metaphases for analysis. For
example, t(4;14) and t(14;16) are cryptic by classical
cytogenetics.1,5
FISH analysis is a high throughput molecular
cytogenetic tool used to detect such cryptic abnormal-
ities.1 However, FISH analysis performed on BM
aspirates of MM patients are technically challenging
because the neoplastic PCs may represent only a small
proportion of the total nuclei present. To overcome
this difﬁculty, several techniques have been advocated.
Some have used antibody-based sorting techniques to
purify PCs from the BM aspirate before FISH analy-
sis. Another proposed technique is to use an initial
May-Grünwald Giemsa stain with mapping of PCs
by image analysis software, followed by subsequent
FISH analysis of the previously mapped PCs.
However, both cell sorting and image analysis tech-
niques involve protocols not routinely performed in
most pathology laboratories. Importantly, none of
the previously published techniques have been appli-
cable to routinely archived BM smears.5
FISH analysis combined with simultaneous
immunoﬂuorescence (IF) using CD138 is an attrac-
tive alternative approach for the evaluation of chromo-
somal changes in MM.5 The use of combined IF and
FISH was ﬁrst reported by Weber-Matthiesen et al.6
as a procedure termed FICTION. So far, FICTION
has been applied to BM smears, peripheral blood (PB)
and cytospin samples with good results. This tech-
nique is potentially very useful due to its easy applica-
bility, rapidity, and amenability to automation. Owing
to its capacity to improve the efﬁcacy of result inter-
pretation (due to the combination of more than one
technique on the same sample), FICTION could be
extremely useful in tumor diagnosis, especially in the
detection of low-level disease, minimal residual disease
(MRD) or diagnosis of composite tumors.7
FISH can be performed on de-waxed tissue sec-
tions, but this technique remains potentially challeng-
ing: the scoring of individual nuclei is difﬁcult due to
cellular overlap and nuclear truncation. Moreover, ﬁx-
ation and embedding procedures may produce artifacts
in tissue, thereby interfering with DNA hybridization.
Alternatively, Buño et al. clearly showed that FISH
using tissue imprints, cytopreps, and BM smears,
including those stored for long periods of time (up to
12 years) is a reliable method to detect abnormalities
with high sensitivity and speciﬁcity.8
The aim of this work is to detect the 14q32 rear-
rangement using FISH analysis combined with simul-
taneous IF on archival BM slides of MM patients and
to study its prognostic value.Hematol Oncol Stem Cell Ther 8(2) Second Quarter 2015SUBJECTS AND METHODS
This study was conducted at Ain Shams University
Hospital, in the period from June 2012 to February
2014, after procuring the approval of the Scientiﬁc
and Ethical Committee of Ain Shams University.
Subjects
The subjects of the study comprised 50 patients ini-
tially diagnosed with MM according to World
Health Organization (WHO) diagnostic criteria for
plasma cell myeloma.9
The archived smears of the BM of 50 MM
patients at the time of ﬁrst diagnosis were collected
for processing.
The clinical, laboratory, and radiological data of
the patients were obtained from patients’ records.
Laboratory data included complete blood count
(CBC), serum protein electrophoresis (SPEP),
Bence Jones protein (BJP) in urine, immuno-ﬁxation
(IFX), serum calcium level, chemistry proﬁle (LDH,
BUN and serum creatinine), serum beta-2-
microglobulin (b2m) and C-reactive protein (CRP).
All patients received bortezomib (VELCADE)-
based combination chemotherapy. This treatment
was composed of bortezomib (1.3 mg/m2; days 1, 4,
8 and 11) plus dexamethasone (40 mg/m2; days 1–4
and 9–12). The cycle was repeated every 3 weeks for
four cycles.
Methods
The following was performed for all patients:
 Morphological re-evaluation of at least two Leishman-
stained smears per patient was performed by two experi-
enced hematologists.
 FICTION technique was used to further analyze the
collected smears and involved a two-step procedure, as
follows:
STEP I: immunoﬂuorescence staining for CD138
(a) FITC-labelled anti-CD138 was diluted in phosphate
buffer saline (PBS) in a ratio of 1:40 and added to
each slide so that it covered the tissue in the marked
area.
(b) The slides were then incubated for 30 min at 37 C
in a dark chamber.
(c) Before performing FISH analysis, the slides were
covered with a cover slip and revised by ﬂuorescence
microscopy for the presence of good IF staining. If
not used immediately, slides were kept at 4 C for
a maximum of 1 week.57
58
original research report 14Q32 REARRANGEMENT IN MM BY FICTION TECHNIQUE
(d) Differential count of CD138 positive cells was done
before performing FISH analysis on the inverted ﬂu-
orescence microscope using the low power magniﬁca-
tion lens (40·).STEP II: ﬂuorescence in situ hybridization (FISH) for
14q32 rearrangement
FISH analysis was performed using Vysis LSI (locus
speciﬁc identiﬁer) IgH dual color, break-apart 14q32
rearrangement probe (Abbott, Germany). 10 ll probe
mixture (7 ll buffer, 1 ll probe 2 ll sterile water) was
added to the marked area on each slide followed by
denaturation (for 5 min at 73 C) using HYBrite
(Vysis) followed by overnight incubation at 37 C.
Post hybridization washes of the slides were per-
formed ﬁrst for 2 min at 73 C in R1 solution
(0.4 · SSC/0.3% NP-40 at pH 6.8–7.2), then
another 2 min at 37 C in R2 solution
(2 · SSC/0.1% NP-40 at pH 7.0–7.5). Finally, slides
were blotted and left to dry in the dark. DAPI II
(4’,6-Diamidino-2-Phenylindole) was then applied to
each slide as counter stain. The slides were scanned
using ﬂuorescent microscope (CytoVision image anal-
ysis system) and signals were viewed in at least 200
interphase cells.
Probe interpretation
CD138-FITC allowed the identiﬁcation and enumer-
ation of cell populations expressing the CD138 anti-
gen, with cells positive for CD138 antigen showing
green rim.
The LSI IgH dual color, break-apart probe was
designed as a dual-color split probe to detect transloca-
tions at 14q32. A break was deﬁned when a red/green
or yellow fusion signal (F) split into separate red and
green signals. Only red and green signals, which were
more than one signal diameter apart from each other,
were counted as a break. Normally, cells showed two
fusion signals. Cells positive for 14q32 rearrangement
showed single fusion signal, one red signal, and one
green signal. To establish the cutoff value for positive
result, 20 archived BM slides of non-malignant cases
and 10 BM slides with reactive increase in the plasma
cells (mean = 6.7 ± 0.7) were examined using the
FISH technique, and the positive result was deter-
mined as the mean + 4SD as described by Cook et al.5
cutoff value was set at more than 4% of the cells.
Statistical methods
Collected data were analyzed using SPSS (version 12)
statistical software package underWindows XP operat-
ing system. Data were expressed as mean ± SD for
quantitative measures, and both number and percentagefor categorical data. Test for data normality was done
using Shapiro–Wilk test. Unpaired t-test and Mann
Whitney test were used to compare parametric and
non-parametric quantitative variables, respectively.
Chi-Square and Fisher’s exact tests were used for
inter-group comparisons.Overall survival (OS)was esti-
mated from the time of diagnosis to the date of death or
last visit. The OS was determined using Kaplan–Meier
curves; log-rank test was used to calculate p value. The
probability of error at<0.05 was considered signiﬁcant.RESULTS
The results of this study are shown in Tables 1 and 2,
Fig. 1, and Photo 1.
This study included 50 MM patients, admitted to
the Hematology Unit at Ain Shams University
Hospital. They comprised 12 (24%) males and 38
(76%) females, with a male to female ratio of 1:3.3.
Their ages ranged from 28 to 74 years (with a mean
of 57.3 ± 11.6 years). Clinical follow-up revealed that
14 of the 50 patients died (28% mortality rate). The
OS of patients ranged from 5 months to 30 months.
Correlation between BM PCs% morphologically
and by CD138 staining (Fig. 1)
A highly signiﬁcant positive correlation was found
between morphologically assessed BM PCs percent-
age and by IF staining for CD138 (r = 0.67,
p = 0.003).
Diagnostic validity of 14q32 rearrangement
detection by FISH and FICTION
Patients were considered positive for presence of
14q32 rearrangement when >4% of cells exhibited it
(out of all cells in case of FISH and out of CD138
positive cells in case of FICTION). A signiﬁcantly
higher percentage of cases were positive for 14q32
rearrangement by FICTION (16/50, 32%) compared
to FISH (6/50, 12%) (v2 = 3.14, p = 0.04).
FICTION was therefore more sensitive than FISH.
Cases positive by FICTION for the rearrangement
(16/50) were designated Group A, while negative
cases were designated Group B.
Comparison between Group A and Group B
(Table 1)
Signiﬁcantly lower Hb and CRP levels were found
among Group B when compared to Group A patients
(p = 0.001 and 0.01, respectively). Although median
level of serum b2m and monoclonal band were higher
in Group B than in Group A, the p value was border-
line (0.06).Hematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
Table 1. Demographic and clinical data in Group A versus Group B.
Parameter Group A
34
Group B
16
Test of significance P
Age: years (median) 60 55 Z = 0.21 0.8
Gender: n (%)
Males 8(23.5) 4(25) Fisher's exact test 1
Females 26(76.5) 12(75)
Lytic bone lesions: n (%)
Nil/solitary 14(41.2) 6(37.5) v2 = 0.061 0.8
Multiple 20(58.8) 10(62.5)
Calcium: mg/dL (median) 9.5 10.4 Z = 0.918 0.3
Creatinine: mg/dL (median) 2.5 1.6 Z = 0.5 0.6
BUN: mg/dL (median) 38 29.5 Z = 0.543 0.5
LDH: IU/L (median) 450 403.5 Z = 0.583 0.5
CRP: mg/L (median) 6 3.5 Z = 2.437 0.01
b2m (mg/L) (median) 19 20.5 Z = 1.834 0.06
Total proteins: g/dL (x € SD) 8.4 € 1.8 8.7 € 1.2 t = 0.609 0.5
Serum albumin: g/dL (median) 4 3.2 Z = 1.549 0.1
BJP: n (%)
Positive 24(70.6) 10(62.5) v2 = 0.327 0.5
Negative 10(29.4) 6(37.5)
Monoclonal band: g/dL (median) 1.8 3 Z = 1.833 0.06
Heavy chain: n (%)
IgG 26(76.5) 16(100) Fisher's exact test 0.04
IgA 8(23.5) 0
Residual c: g/dL (median) 0.3 0.4 Z = 1.3 0.1
WBC: ·109/L (mean € SD) 7.6 € 2.6 6.3 € 3.1 t = 1.607 0.1
Hb: g/dL (median) 7.8 5.4 Z = 3.457 0.001
PLT: ·109/L (mean € SD) 194.5 € 86.7 172.3 € 80.6 t = 0.866 0.3
BM plasma cells% (median) 33 28 Z = 1.461 0.1
n, number; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; CRP, C-reactive protein; BJP, Bence Jones protein; BM, bone marrow.
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The mean survival for all patients was
13.3 ± 6.6 months. The impact of selected poor prog-
nostic factors, according to Dmoszynska,10 on the OS
of the presently studied MM patients revealed that
serum albumin level and BJP signiﬁcantly affected OS
(p = 0.01, 0.007, respectively). Regarding the effect ofHematol Oncol Stem Cell Ther 8(2) Second Quarter 201514q32 rearrangement using FICTION technique,
shorter mean survival time was found in positive cases;
however, the p value was not statistically signiﬁcant.
The effect of b2m and LDH levels on OS could
not be studied because all MM patients expressed
high levels that exceeded the suggested levels for dis-
criminating poor versus good prognosis.59
Table 2. Impact of different prognostic factors on OS of the MM patients.
Parameters (N) Mortality (%) Means survival time (months) 95% CI Log rank P
Estimate SE
Age (years)
65 (30) 8 (27) 23.53 1.96 19.69–27.37 0 0.9
>65 (20) 6 (30) 23.5 2.22 19.15–27.85
PLT count
<130 · 109/L (10) 2 (20) 12.2 0.51 11.21–13.19 0.59 0.4
130 · 109/L (40) 12 (30) 22.95 1.71 19.61–26.29
Serum albumin
<3.5 g/L (22) 10 (45) 10.27 0.67 8.96–11.58 5.75 0.01
3.5 g/L (28) 4 (14) 26.64 1.56 23.59–29.7
Heavy chain
IgG (42) 14 (33) 22.29 1.69 18.98–25.59 3.26 0.07
IgA (8) 0 * * *
BJP
Absent (16) 8 (50) 26.06 1.46 23.19–28.93 7.1 0.007
Present (34) 6 (18) 18.13 2.98 12.29–23.96
14q32 rearrangement by FICTION
Positive (16) 6 (38) 11.6 1.1 9.5–13.8 1.63 0.2
Negative (34) 8 (24) 24.7 1.6 21.5–27.9
N, number; BJP, Bence Jones protein.
*Survival estimates cannot be computed.
Figure 1. Correlation between morphologically assessed BM PCs percentage and by CD138 staining.
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In the present study, the percentage of PCs was esti-
mated using CD138 immuno-stained BM slides of
MM patients as compared to their traditionaldifferential count of BM PCs. This IF slide technique
gave a higher percentage of positive cases, compared
to that estimated by morphological assessment of
Leishman-stained smears. Smith and Elnawawi11
reported that CD138 immuno-staining achievesHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
Photo 1. Positive FICTION technique: CD138 positive cells show green rim; cells positive for 14q32 rearrangement show single fusion signal, one
red signal, and one green signal.
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makes it possible to recognize PCs under low-
magniﬁcation microscopy when their numbers can
be better judged in relation to other cells of the mar-
row. Thus, CD138 estimates improved the diagnostic
accuracy of counting PCs in MM. The same authors
also reported a more accurate estimate of the PC pop-
ulation within the entire BM core biopsy using IF
staining for CD138 than the Giemsa-stained aspirate
smears and Hematoxylin-Eosin (H&E) sections.
Stifter and colleagues12 recommended the combined
analysis of BM aspirates and core biopsies, using the
IF staining for CD138 of BM PCs to achieve more
accurate and informative data on the diagnosis of
PC inﬁltrates of BM. PC quantiﬁcation is also used
in the evaluation of morphological remission and min-
imal residual disease (MRD) in MM patients. A high
percentage of PC inﬁltration in BM has been recog-
nized as a reliable predictor of relapse in cases of trea-
ted MM. The PC fraction in the BM is therefore
critical for the classiﬁcation and optimal clinical man-
agement of patients with MM.12
In the present study, FISH analysis was used with
simultaneous CD138 IF on archived BM smears. The
CD138 IF allows the identiﬁcation and enumeration
of PCs and improves the sensitivity of the FISH
method, in accordance with the reports of previous
studies.1,5,13,14
To establish the cutoff value for positive results, 20
archived BM slides of non-malignant cases and 10 BMHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015slides with reactive increase in the plasma cells were
examined using the FISH technique. Our cutoff value
was set at more than 4% of the cells. This is in accor-
dance with Cook et al.5 who examined parafﬁn sections
of formalin-ﬁxed and bonemarrow clot preparations by
FICTION technique in MM cases using CD138 and
break-apart probe for IGH translocations. They used
intact parafﬁn sections of only ﬁve cases of reactive lym-
phoid hyperplasia as negative controls. They estab-
lished cutoff thresholds for interpretation at four
standard deviations above the mean of the negative con-
trols, yielding cutoffs of >5%.
FICTION technique was found in the present
study to bemore sensitive than FISH analysis in detect-
ing 14q32 rearrangements in archived BM aspirate
smears (32% versus 12%, respectively). In 2006, Cook
et al.5 reported that scoring of only CD138-positive
PCs allow efﬁcient detection of myeloma-associated
chromosomal abnormalities, which may be demon-
strated in a very high proportion of plasma cells
counted, even when the overall percentage of plasma
cells in the marrow is low. This technique offers several
advantages over other proposed methods. Unlike tech-
niques using cytoplasmic immunoglobulin light chain
staining, prior knowledge of the restricted light chain
involved is not required. Specialized procedures such
as cell sorting or computerized image analysis are
unnecessary. Most importantly, this technique is appli-
cable to routinely archived, formalin-ﬁxed, parafﬁn-
embedded and BM clot preparations. Therefore, this61
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method allows for both prospective analysis and retro-
spective studies of previously archived and even
parafﬁn-embedded material.6
In the present study, a signiﬁcant association was
found between the presence of 14q32 rearrangements
and an IgG isotype. Interestingly, in 2002, Moreau
et al.15 investigated 168 MM patients and found a
strong positive correlation between t(4;14) and IgA iso-
type, with no correlation observed in patients with
translocations involving another partner, or those lack-
ing any 14q32 rearrangement. Additionally, Chen
et al.13 studied 48 newly diagnosed untreated MM
patients, using interphase FISH and reported no corre-
lation between 14q32 rearrangements and the type of
para-protein.
In 2002, Avet-Loiseau and colleagues16 reported a
strong association of b2m to t(4;14) and t(14;16), but
not to t(11;14), or to patients lacking 14q32 rear-
rangements. In the present study, the association
between b2m and 14q32 rearrangements was of bor-
derline signiﬁcance. This could be attributed to the
conglomerate approach of FICTION to 14q32 rear-
rangements in the present study versus studying each
translocation partner separately.
The survival of myeloma patients is highly variable,
ranging from few months to more than 10 years. This
heterogeneity is related mainly to prognostic factors
associated with speciﬁc characteristics of both the
tumor itself and the host.17
In the present work, there was a non-signiﬁcant
association between 14q32 rearrangements and
shorter OS. Moreau et al.,15 Dewald et al.,18 and
Gertz et al.19 reported that patients with t(4;14)
and t(14;16) had shorter OS, while patients with
t(11;14) had exceptionally long OS survival. The
inability to establish a signiﬁcant association between
OS and the presence of 14q32 rearrangements in the
present work may be in part due to the heterogeneous
impact of different partner chromosomes on survival,
or due to the short duration of follow up in relation to
the median survival of patients in records.
An ideal prognostic model should associate cytoge-
netics to other prognostic parameters. This justiﬁesthe routine application of FICTION in the workup
of all newly diagnosed and relapsed myeloma patients,
where a more precise prognostic classiﬁcation and
therapeutic management focuses on the molecular
genetics of every patient, as the patient-dependent
toxicity of most drugs available for myeloma treat-
ment is related to constitutional genetic variability.
The detection of t(4;14), t(14;16), deletion 13 and
deletion of p53 by FICTION will deﬁne high-risk
prognostic groups that are not generally controlled
with high-dose melphalan and autologous stem cell
transplantation (ASCT), and should therefore be
treated with investigational therapies. On the other
hand, patients who do not have these poor risk factors
are more likely to beneﬁt from a high-dose melphalan-
based regimen followed by ASCT. More intensive
chemotherapy accompanied by transplantation, tan-
dem ASCT, as well as targeted therapies (e.g., borte-
zomib and thalidomide), should be carefully evaluated
in an effort to distinguish those patient subgroups
more likely to respond, and to gain maximum proﬁt
from the appropriate therapeutic agent.20
Finally, the present work concluded that FICTION
technique provides amore sensitive tool for establishing
clonal PC inﬁltration of BM aspirates, and is amenable
for use on archived as well as fresh smears. The use of
the FICTION technique is recommended for the
simultaneous detection of other clinically relevant chro-
mosomal abnormalities in MM, lymphoma, and other
hematological malignancies.CONFLICT OF INTEREST
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